Диссертация (1154341), страница 44
Текст из файла (страница 44)
40(2). — P. 246-9.127. CyclinD1, a prominent prognostic marker for endometrial diseases /Liang S., Mu K., Wang Y., Zhou Z. [et al.] // Diagn. Pathol. — 2013. — N. 15. — P. 138.128. Decidual PTEN expression is required for trophoblast invasion in themouse / Lague M.N., Detmar J., Paguet M., Boyer A. [et al.] // Am. J. Physiol.273Endocrinol. Metab. — 2010. — N.
299(6). — P. 936-46.129. Diagnosis and management of endometrial hyperplasia / Armstrong A.J.,Hurd W.W., Elguero S., Barker N.M. [et al.] // J. Minim. Invasive Gynecol. — 2012. —N. 19(5). — P. 562-571.130. Diagnostic accuracy of liquid-based endometrial cytology in the evaluationof endometrial pathology in postmenopausal women / Remondi C., Sesti F., Bonanno E.,Pietropolli A. [et al.] //Cytopathology. — 2013. — N. 24(6). — P. 365-71.131. Diagnostic accuracy of saline infusion sonography in the evaluation ofuterine cavity abnormalities prior to assisted reproductive techniques: a systematic reviewand meta-analyses / Seshadri S., El-Toukhy T., Douiri A.
[et al.] / Hum. Reprod.Update. — 2015. — Vol. 21. — Iss. 2. — P. 262-274.132. Diagnostic accuracy of sonohysterography and transvaginal sonography ascompared with hysteroscopy and endometrial biopsy: a prospective study / La Sala G.B.,Blasi I., Gallinelli A., Debbi C. [et al.] // Minerva Ginecol. — 2011.
— N. 63(5). —P. 421-7.133. Endometrial cancer and genetic variation in PTEN, PIK3CA, Aktl, MLH1and MSH2 within a population-based case-control study / James V. Lacey Jr, HannahYang, Mia M. Gaudet, Alison Dunning [et al.] // Gynecologic Oncology. — 2011. —N. 120. — P. 167-173.134. Endometrial hyperplasia - the dilemma of management remains: aretrospective observational study of 280 women / Daud S., Jalil S.S., Griffin M.,Ewies A.A. // Eur.
J. Obstet. Gynecol. Reprod. Biol. — 201. — N. 159(1). — P. 172-5.135. Endometrial polyp surveillance in premenopausal breast cancer patientsusing tamoxifen / Jeon S.J., Lee J.I., Lee M., Kim H.S. [et al.] // Obstet. Gynecol. Sci. —2017. — Vol.
60(1). — P. 26-31.136. Endometrial thickness measurement for detecting endometrial cancer inwomen with postmenopausal bleeding: a systematic review and meta-analysis /Timmermans A., Opmeer B.C., Khan K.S. [et al.] // Obstet. Gynecol. — 2010. —Vol. 116. — P. 160–167.137. Evaluation of the histopathological diagnosis of patients preoperatively274diagnosed with atypical endometrial hyperplasia after hysterectomy / Kurt S.,Demirtaş O., Kopuz A., Beyan E. [et al.] // Eur.
J. Gynaecol. Oncol. — 2012. —N. 33(5). — P. 459-62.138. Expression of ER-α36, a novel variant of estrogen receptor in endometrialcarcinoma and its clinical significance / Sun L., Wang J., Zhang L., Li X. [et al.] //Gynecol. Obstet. Invest. — 2013. N. 75(1). — P. 68-72.139. Expression of ER-α36, a novel variant of estrogen receptor in endometrialcarcinoma and its clinical significance / Sun L., Wang J., Zhang L., Li X., Shen D.
//Gynecol. Obstet. Invest. — 2013. — N. 75(1). — P. 68-72.140. Expression of metabolically targeted biomarkers in endometrial carcinoma /Wahl H., Daudi S., Kshirsagar M. [et al.] // Gynecologic Oncology. — 2010. —N. 116. — P. 21-7.141. Fertility-preserving treatment in young women with well-differentiatedcarcinoma and severe atypical hyperplasia of endometrium / Yu M., Yang J.X.,Lang J.H., Huo Z. // Fertil. Steril.
— 2009. — N. 92(6). – P. 2122-6.142. Gallos, I.D. Comment on: What about the relapse of endometrialhyperplasia? / Gallos I.D., Gupta J.K. // Eur. J. Obstet. Gynecol. Reprod. Biol. —2013. — N. 171(2). — P. 5.143. Galv, R. Three-dimensional power Doppler angiography in endometrialcancer: correlation with tumor characteristics / Galv R., Merc L., Jurado M. // UltrasoundObstet. Gynecol. – 2010. – V. 35.6. – P. 723-729.144.
Histopathologic assessment of the entire endometrium in asymptomaticwomen / Menzies R., Wallace S., Ennis M., Bennett A. // Hum. Pathol. — 2013. —N. 44(10). – P. 2293-301.145. Hysteroscopic inspection and total curettage are insufficient fordiscriminating endometrial cancer from atypical endometrial hyperplasia / Kurosawa H.,Ito K., Nikura H., Takano T. [et al.] // Tohoku J. Exp.
Med. — 2012. — N. 228(4). —P. 365-70.146. Identifyingestrogenreceptorstargetgenes/WelborenW.J.,Strunnenberg H.G., Sweep F.C., Span P.N. // Mol. Oncol. — 2010. —N. 1. — P. 138-275147.147. Image analysis and multi-layer perceptron artificial neural networks for thediscrimination between benign and malignant endometrial lesions / Makris G.M.,Pouliakis A., Siristatidis C., Margari N.
[et al.] // Diagn. Cytopathol. — 2017. —Vol. 45(3). — P. 202-211.148. Immunohistochemical markers in endometrial hyperplasia: is there a panelwith promise? A Review / K. H. Allison [et al.] // Appl. Immunohistochem. Mol.Morphol. – 2008. – Vol. 16 (4). – P. 329-343.149. Incidence of endometrial hyperplasia / Reed S.D., Newton K.M.,Clinton W.L., Epplein M. [et al.] // Am.
J. Obstet. Gynecol. — 2009. — N. 200. — P. 678.150. Indirect mechanisms of carcinogenesis via downregulation of PTENfunction / Leslie N.R., Spinelli L., Tibarewal P., Zilidis G. [et al.] // Advances in EnzymeRegulation. — 2010. — N. 50. — P. 112-118.151.
Infertility and incident endometrial cancer risk: a pooled analysis from theepidemiology of endometrial cancer consortium (E2C2) / Yang H.P., Cook L.S.,Weiderpass E. [et al.] // British Journal of Cancer. — 2015. — Vol. 112. — P. 925-933.152. Intrauterine levonorgestrel delivery with frameless fibrous delivery system:review of clinical experience / Wildemeersch D., Andrade A., Goldstuck N.D.,Hasskamp T.
[et al.] // Int. J. Womens Health. — 2017. — Vol. 21. — Iss. 9. — P. 49–58.153. Jakubowska, А. Lack of evolutionary conservation at positions important forthermal stability in the yeast ODCase protein / Jakubowska А., Korona R. // Mol. Biol.Evol. — 2009. — N. 26(7). — P. 1431-4.154. Jarboe, E.A. Endometrial intraepithelial neoplasia / Jarboe E.A.,Mutter G.L.
// Semin. Diagn. Pathol. — 2010. — N. 27(4). — P. 215-25.155. Jianying, X.U. Expression of Survivin Gene among Human NormalEndometrium, Atypical Hyperplasia of Endometrium and Endometrial Carcinoma /Jianying X.U., Shufang Wang, Zhongyan Wan // Journal of Reproduction andContraception. — 2010. — N. 21 (3). — P. 129–135.156. Joshi, A. Adenovirus mediated homozygous endometrial epithelial PTEN276deletion results in aggressive endometrial carcinoma / A. Joshi, L.H. Ellenson //Experimental Cell Research. — 2011.
— P. 1580-1589.157. Kotdawala, P. Evaluation of endometrium in peri-menopausal abnormaluterine bleeding / Kotdawala P., Kotdawala S., Nagar N. // J. Midlife Health. — 2013. —N. 4(1). – P. 16-21.158. Leptin receptor expression during the progression of endometrial carcinomais correlated with estrogen and progesterone receptors / Méndez-López L.F., ZavalaPompa A., Cortés-Gutiérrez E.I., Cerda-Flores R.M. [et al.] // Arch. Med.
Sci. — 2017. —Vol. 1. — Iss. 3(1). — P. 228-235.159. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: along-term comparative cohort study / I. D. Gallos [ et al. ] // Hum. Reprod. – 2013. –Vol. 28 (11). – P. 2966-2971.160. Management of reproductive health in Cowden syndrome complicated byendometrial polyps and breast cancer / Kalin A., Merideth M.A., Regier D.S.,Blumenthal G.M. [et al.] // Obstet. Gynecol. — 2013. — N. 121.
— P. 461-4.161. Marsden, D.E. Optimal management of endometrial hyperplasia /Marsden D.E., Hacker N.F. // Best Pract. Res. Clin. Obstet. Gynaecol. — 2011. —N. 15(3). — P. 393-405.162. Mitochondrial DNA content and mass increase in progression from normalto hyperplastic to cancer endometrium / Cormio A., Guerra F., Cormio G., Pesce V. [etal.] // BMC Res. Notes. — 2012. — N. 7. — P. 279.163. Mohamed A.M. Abraheem Serum and tissue angiogenin in patients withendometrial hyperplasia / Mohamed A.M., Naglaa F. // Middle East Fertility SocietyJournal. — 2010.
— N. 15. — P. 248-252.164. Molecular biomarkers in endometrial hyperplasias predict cancerprogression / A. Steinbakk [ et al.] // Am. J. Obstet. Gynecol. – 2011. – Vol. 204 (4). – P.357.165. Molecular pathology of endometrial carcinoma: practical aspects from thediagnostic and therapeutic viewpoints / Llobet D., Pallares J., Yeramian A. [et al.] // J.Clin. Pathol.
— 2009. — N. 116. — P. 21-7.277166. Molecular profiles of benign and (pre)malignant endometrial lesions / Vander Putten L.J.M., Van Hoof R., Tops B.B.J., Snijders M.P.L.M. [et al.] //Carcinogenesis. — 2017. — Vol. 1. — Iss. 38(3). — P. 329-335.167. Morphological diagnosis of endometrial intraepithelial neoplasia andexpression of PTEN / Zhou W.X., Lianq Z.Y., Gao J., Liu T.H.
// Zhonghua Binq Li XueZa Zhi. — 2009. — N. 38(6). — P. 3939-6.168. Mountzios, G. Developments in the systemic treatment of endometrialcancer / Mountzios, G., Pectasides D., Bournakis E. // Critical Reviews in Oncology /Hematology. — 2011. — N. 79. — P. 278-292.169. Mutual contribution of PTEN and estrogen to endometrial carcinogenesis ina PtenloxP/lox P Mouse Model / Saito F., Tashiro H., To Y., Ohtake H. [et al.] // Int. J.Gynecol. Cancer. — 2011. — N.
21(8). — P. 1343-9.170. Heavy menstrual bleeding: assessment and management. NICE Clinicalguideline 44, 2007. — Режим доступа: https://www.nice.org.uk/guidance/cg44.171. Norimatsu, Y. Utility of liquid-based cytology in endometrial pathology:diagnosis of endometrial carcinoma / Norimatsu Y., Kobayashi T., Kouda H.
//Cytopathology. — 2009. — N. 20(6). — P. 395-402.172. Nomura, H. Clinical Management of HBOC in Our Hospital / Nomura H.,Takeshima N. // Gan To Kagaku Ryoho. — 2017. — Vol. 44(2). — P. 116-120.173. Oral contraceptive use and risk of breast, cervical, colorectal, andendometrial cancers: a systematic review / Gierisch J., Coeytaux R., Urrutia R. [et al.] //Cancer Epidemiol.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
